Cargando…
State of Art of Idiosyncratic Drug-Induced Neutropenia or Agranulocytosis, with a Focus on Biotherapies
Introduction: Idiosyncratic drug-induced neutropenia and agranulocytosis is seldom discussed in the literature, especially for new drugs such as biotherapies outside the context of oncology. In the present paper, we report and discuss the clinical data and management of this relatively rare disorder...
Autores principales: | Andrès, Emmanuel, Lorenzo Villalba, Noel, Zulfiqar, Abrar-Ahmad, Serraj, Khalid, Mourot-Cottet, Rachel, Gottenberg, Jacques-Eric |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6788182/ https://www.ncbi.nlm.nih.gov/pubmed/31480527 http://dx.doi.org/10.3390/jcm8091351 |
Ejemplares similares
-
Idiosyncratic Drug-Induced Neutropenia and Agranulocytosis in Elderly Patients
por: Lorenzo-Villalba, Noel, et al.
Publicado: (2020) -
Severe Neutropenia and Agranulocytosis Related to Antithyroid Drugs: A Study of 30 Cases Managed in A Single Reference Center
por: Andrès, Emmanuel, et al.
Publicado: (2020) -
Idiosyncratic Drug-Induced Severe Neutropenia and Agranulocytosis in Elderly Patients (≥75 years): A Monocentric Cohort Study of 61 Cases
por: Mourot-Cottet, Rachel, et al.
Publicado: (2016) -
Drug-Induced Idiosyncratic Agranulocytosis - Infrequent but Dangerous
por: Rattay, Bernd, et al.
Publicado: (2021) -
Agranulocytosis under biotherapy in rheumatoid arthritis: three cases hypothesis of parvovirus B19 involvement in agranulocytosis observed under tocilizumab and rituximab for the treatment of rheumatoid arthritis
por: Giraud, C., et al.
Publicado: (2016)